A Major Breakthrough in Venous Disease Treatment

We are developing BioVena™, a less-invasive, effective, pain-free and faster minimally invasive endovenous treatment for all chronic venous disease patients. BioVena™ is the world ’s first effective non-thermal medical device to cure varicose veins and venous ulcers, collectively known as chronic venous disease*. BioVena™ uses the body’s natural healing response to cure symptoms allowing all chronic venous disease sufferers receive treatment for the first time.

Chronic Venous Disease

Chronic Venous disease (CVD) is when blood is not circulated effectively around the body. It is caused by the failure of one-way valves responsible for preventing blood flowing backwards in veins and results in blood pooling in the legs. Chronic Venous Disease is a progressive spectrum of symptoms where 5% of sufferers experience more advanced symptoms every year.

Symptoms begin with varicose veins, which are dilated, tortuous veins. This can progress to pain, heaviness and leg swelling, eczema and subsequent skin changes leading to the breakdown of the skin, and malodorous leaking venous ulceration, in addition to cosmetic dissatisfaction.

This is a progressive and devastating disease which destroys Quality of Life for patients who experience advanced symptoms.

A Huge Underestimated Healthcare Need

Venous disease affects one in four people and ranks as the 4th most common chronic disease in the world. This progressive venous disease culminates in debilitating venous leg ulcers that destroy quality of life for sufferers. It places a huge burden on health care systems, representing up to 3% of total healthcare budgets of western countries.

Only 1.3% of the 120 million people in the US & Europe who suffer from venous disease currently receive treatment each year.

BioVena™ offers an unrivalled lower risk treatment which will allow more patients who suffer from venous disease to access effective treatment*.

* – BioVena™ is currently for Investigational Research Use Only. Regulatory approval is anticipated in 2021.